Expand all sections

Tavokinogene telseplasmid

Tavo

Extended indication Patients with stage III/IV metastatic melanoma who have failed or are failing on anti-PD-1 therapies
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Tavokinogene telseplasmid
Domain Oncology
Reason of inclusion New medicine (specialité)
Main indication Skin cancer
Extended indication Patients with stage III/IV metastatic melanoma who have failed or are failing on anti-PD-1 therapies (like nivolumab and pembrolizumab) in combination with pembrolizumab.
Proprietary name Tavo
Manufacturer OncoSec
Mechanism of action Immunostimulation
Route of administration Intratumoral
Therapeutical formulation Injection
Budgetting framework Intermural (MSZ)
Additional remarks Tavokinogene telsaplasmid codeert voor IL-12, een immunostimulant. Electroporatie via ImmunoPulse is benodigd voor de activatie van tavokinogene telsaplasmid in het tumorweefsel.

Registration

Registration route Centralised (EMA)
ATMP Yes
Submission date September 2022
Expected Registration October 2023
Orphan drug No
Registration phase Registration application pending
Additional remarks Heeft een wees status bij de FDA.

Therapeutic value

Therapeutic value No estimate possible yet
References NCT03132675
Additional remarks Patiënten worden behandeld met intratumorale tavo-EP op dag 1, 5 en 8 iedere 6 weken en met intraveneuze toediening van pembrolizumab (200mg) op dag 1 van iedere 3-weekse cyclus gedurende 17 tavo-EP cycli en 33 pembrolizumab cycli.

Expected patient volume per year

Patient volume

< 775

Market share is generally not included unless otherwise stated.
References NKR
Additional remarks Melanoom van de huid betreft 6.746 patiënten in 2020, hiervan zijn er 687 patiënten met stadium 3 en 88 patiënten met stadium 4 (maximaal 775 patiënten die in aanmerking komen voor deze behandeling.)

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

Off label use Yes
Indications off label use Melanoma patients with immunologically cold tumors; eoadjuvant resectable melanoma; R/R squamous cell carcinoma of the head and neck (SCCHN); triple negative breast cancer (TNBC).
References OncoSec pipeline

Indication extension

Indication extension No
References adisinsght
Additional remarks Geen lopende fase 3 studies.

Other information

There is currently no futher information available.